- Home
- AKRO vs IBRX Comparison
AKRO vs IBRX Comparison
Compare AKRO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- IBRX
- Stock Information
- Founded
- AKRO 2017
- IBRX 2014
- Country
- AKRO United States
- IBRX United States
- Employees
- AKRO N/A
- IBRX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKRO Health Care
- IBRX Health Care
- Exchange
- AKRO Nasdaq
- IBRX Nasdaq
- Market Cap
- AKRO 1.8B
- IBRX 1.9B
- IPO Year
- AKRO 2019
- IBRX N/A
- Fundamental
- Price
- AKRO $51.84
- IBRX $3.42
- Analyst Decision
- AKRO Strong Buy
- IBRX Strong Buy
- Analyst Count
- AKRO 9
- IBRX 3
- Target Price
- AKRO $75.86
- IBRX $13.58
- AVG Volume (30 Days)
- AKRO 2.2M
- IBRX 6.0M
- Earning Date
- AKRO 03-03-2025
- IBRX 03-18-2025
- Dividend Yield
- AKRO N/A
- IBRX N/A
- EPS Growth
- AKRO N/A
- IBRX N/A
- EPS
- AKRO N/A
- IBRX N/A
- Revenue
- AKRO N/A
- IBRX $7,332,000.00
- Revenue This Year
- AKRO N/A
- IBRX $2,359.81
- Revenue Next Year
- AKRO N/A
- IBRX $808.10
- P/E Ratio
- AKRO N/A
- IBRX N/A
- Revenue Growth
- AKRO N/A
- IBRX 1218.71
- 52 Week Low
- AKRO $17.86
- IBRX $2.28
- 52 Week High
- AKRO $58.40
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- AKRO 65.39
- IBRX 52.26
- Support Level
- AKRO $48.70
- IBRX $3.35
- Resistance Level
- AKRO $51.40
- IBRX $4.27
- Average True Range (ATR)
- AKRO 2.29
- IBRX 0.31
- MACD
- AKRO -0.90
- IBRX 0.04
- Stochastic Oscillator
- AKRO 35.50
- IBRX 29.17
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.